Global Sickle Cell Disease Pipeline Drugs and Companies Report 2021 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Sickle Cell Disease Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials” report has been added to ResearchAndMarkets.com’s offering.

Sickle Cell Disease pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “Sickle Cell Disease pipeline drugs and companies” presents key-decision makers with critical insights into Sickle Cell Disease pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

The Sickle Cell Disease pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Sickle Cell Disease. In addition to recent status, overview of drugs is included in the study. Wide range of Sickle Cell Disease drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

The Sickle Cell Disease pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Sickle Cell Disease pipeline candidates is provided in the report enables you to understand timetable developments in Sickle Cell Disease therapeutic area.

Details of technologies used for development of Sickle Cell Disease pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Sickle Cell Disease research study. Companies looking to partner with other players are also detailed in the report.

Sickle Cell Disease pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different Sickle Cell Disease companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Sickle Cell Disease drug administration.

Sickle Cell Disease companies and Profiles

Companies developing Sickle Cell Disease pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Reasons to Buy

• Make better-informed decisions based on the current status of each of the pipeline drug candidate
• Identify new business opportunities by evaluating the progress of the Sickle Cell Disease R&D pipeline
• Analyze the market and research segments based on a comprehensive analysis of Sickle Cell Disease pipeline drugs and clinical trials
• Identify Sickle Cell Disease drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
• Gain clear understanding of the Sickle Cell Disease drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
• Check the Sickle Cell Disease pipeline progress of target companies and key strategies of leading players
• Gain real-time insights into the global Sickle Cell Disease pipeline news, developments and insights

Key Topics Covered:

1. Table of Contents

2. Executive Summary

3 Sickle Cell Disease Pipeline Snapshot, 2021

3.1 Sickle Cell Disease Pipeline Drugs- Dominant phase type

3.2 Sickle Cell Disease pipeline Drugs- Leading Mechanism of Action

3.3 Sickle Cell Disease Pipeline Drugs- Widely researched Route of Administration

3.4 Sickle Cell Disease Pipeline- New Molecular Entity

3.5 Sickle Cell Disease pipeline- Companies, Universities and Institutes

4. Sickle Cell Disease Drug Profiles

4.1 Current Status of Sickle Cell Disease Drug Candidates, 2021

4.2 Sickle Cell Disease Drugs in Development- Originator/Licensor

4.3 Sickle Cell Disease Drugs in Development- Route of Administration

4.4 Sickle Cell Disease Drugs in Development- New Molecular Entity (NME)

5. Sickle Cell Disease Clinical Trials

5.1 Preclinical Trial details

5.2 Phase 1 Clinical Trial Details

5.3 Phase 2 Clinical Trial Details

5.4 Phase 3 Clinical Trial Details

6. Sickle Cell Disease Companies and Universities

6.1 Leading Sickle Cell Disease companies researching in drug development

6.2 Leading Sickle Cell Disease Universities/Institutes investing in drug development

7. Sickle Cell Disease News and Deals

7.1 Recent Sickle Cell Disease Market Developments

7.2 Pipeline Drug News Updates

7.3 Pipeline Company updates

8. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/a7kdqn

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900